Somatic POLE Mutation and Ultra-Hypermutated Genotype in a De Novo High-Grade, Isocitrate Dehydrogenase Wild-Type Glioma: Treatment Implications

JCO Precis Oncol. 2024 Jan:8:e2300324. doi: 10.1200/PO.23.00324.

Abstract

Pembrolizumab leads to a durable response in ultra-hypermutated, high-grade, glioma.

MeSH terms

  • Brain Neoplasms* / drug therapy
  • Brain Neoplasms* / genetics
  • Genotype
  • Glioma* / drug therapy
  • Glioma* / genetics
  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Mutation

Substances

  • Isocitrate Dehydrogenase